Limitations to antiarrhythmic drug use in patients with atrial fibrillation

Humphries, Karin H.; Kerr, Charles R.; Steinbuch, Michael; Dorian, Paul
September 2004
CMAJ: Canadian Medical Association Journal;9/28/2004, Vol. 171 Issue 7, p741
Academic Journal
Background: Of the antiarrhythmic agents currently marketed in Canada, 5 are commonly used to treat atrial fibrillation (AF). The impact of contraindications, warnings and precautions for the use of these drugs in patients with AF is not known. We evaluated the proportion of patients with AF for whom contraindications, warnings and/or precautions might limit the use of these commonly prescribed drugs and the proportion of patients actually receiving antiarrhythmic drugs despite the presence of contraindications and/or warnings. Methods: A total of 723 patients with electrocardiographically confirmed, new-onset paroxysmal AF who were enrolled in the Canadian Registry of Atrial Fibrillation were used in this analysis. The 1996 Compendium of Pharmaceuticals and Specialties was used to obtain contraindications, warnings and precautions for use of 5 antiarrhythmic drugs: flecainide, quinidine, sotalol, amiodarone and propafenone. Proportions of patients with contraindications, warnings and/or precautions for use of any of these drugs owing to comorbid conditions or concomitant drug therapy were calculated, regardless of whether the drugs had been prescribed. We then calculated the proportion of patients taking each antiarrhythmic drug at 3 months despite contraindications and/or warnings. Results: At baseline, when conditions for contraindications and warnings were combined, 414 (57%), 235 (33%), 327 (45%), 285 (39%) and 272 (38%) patients had restrictions for the use of flecainide, quinidine, sotalol, amiodarone and propafenone respectively. Among 465 patients actually taking these medications at 3-month follow-up, 33.3% (2/6), 83.3% (40/48), 36.4% (92/253), 64.1% (25/39) and 34.5% (41/119) respectively had contraindications and/or warnings against their use. The burden of comorbid disease among patients with AF was noteworthy: 404 (56%) had structural heart disease, which included 227 (31%) with ischemic heart disease, 158 (22%) with left ventricular systolic...


Related Articles

  • World Atrial Fibrillation Awareness Day - It's About Time! Lakkireddy, Dhanunjaya // JAFIB: Journal of Atrial Fibrillation; 

    The author reflects on the prevalence of Atrial Fibrillation (AF) which have increased and relatively not common before the age of 60 years affecting 10% of population in the U.S. He states that coronary artery disease happens due to functional stenosis or mechanical obstruction of coronary...

  • Murmurs about the heart. Laborde, Karen L. // New Orleans Magazine;Feb2000, Vol. 34 Issue 5, p28 

    Focuses on the prevention and treatment of coronary-artery disease. INSET: Risk Factors for Coronary-Artery Disease.

  • Comorbidities Complicate a Diabetic Man's Care. Steingart, Richard M. // Cortlandt Forum;3/25/2003, Vol. 16 Issue 3, p102 

    Discusses the management of coronary artery disease. Findings of symptom-limited stress test; Importance of weight loss in diabetic patients; Frequency of prevention services in physician specialties.

  • Coronary disease. Hart, Julian Tudor // British Medical Journal (Clinical Research Edition);7/31/1982, Vol. 285 Issue 6338, p345 

    Examines the clinical management for coronary diseases. Preventive mechanism for the disease; Role of the cardiologist in ensuring proper medical care for affected patients; Signs and symptoms of coronary diseases.

  • Abstracts of the 2008th Encouragement Award's Memorial Lecture.  // Journal of Nippon Medical School;2009, Vol. 76 Issue 1, p38 

    The article offers information on the study of substrates for atrial fibrillation (AF). Researchers conducted the trial of AF in hearts of myocardial infarction patients. It was discovered that heterogeneous pulmonary vein myocardial cell repolarization and heterogeneous sympathetic...

  • Atrial fibrillation after surgical revascularization: is there any difference between on-pump and off-pump? Enc, Yavuz; Ketenci, Bulent; Ozsoy, Deniz; Camur, Gercek; Kayac─▒oglu, Ilyas; Terzi, Sait; Cicek, Sertac // European Journal of Cardio-Thoracic Surgery;Dec2004, Vol. 26 Issue 6, p1129 

    Abstract: Objective: Postoperative atrial fibrillation (AF) is still frequent complication after cardiac surgery in spite of the improvements in the surgical procedures. There is still controversy whether or not, the absence of cardiopulmonary bypass results in a lower incidence of AF. Methods:...

  • Direct Thrombin Inhibitors Soon Available to Prevent Stroke in Atrial Fibrillation Patients. Fink, Matthew E. // Neurology Alert;Nov2011, Vol. 30 Issue 3, p20 

    The article discusses the addition of two direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF) was designed to test rivaroxaban in a double blind trial against warfarin. Also, Apixaban versus...

  • INTRODUCTION. Myerburg, Robert J. // Journal of Cardiovascular Pharmacology & Therapeutics;Jan2001, Vol. 6 Issue 1, p67 

    The article presents information on the symposium "Designing Antiarrhythmic Therapy--Lessons from the 20th Century." Primary issues of antiarrhythmic strategies include effect, safety, and tolerance. The symposium begins with physician John Camm's discussion on clinical trials, focusing...

  • Experts debate using risk or expected benefit for determining when to start stain therapy.  // Formulary;Nov99, Vol. 34 Issue 11, p908 

    Presents perspectives on the use of statin therapy for primary prevention of coronary artery diseases. Initiation of statins for primary prevention guided by the risk of future cardiovascular events; Multifactorial approach to guide treatment decisions; Statin therapy guided by the expected...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics